Sort
85,873 grants matching “alzheimers”
Photocleavage Technology for Blood-based Multi-Biomarker Alzheimer's Disease Assay
$1,249,958Mark Lim · Ambergen, Inc · R44 · FY2021 · AG
Photocleavage Technology for Blood-based Multi-Biomarker Alzheimer's Disease Assay
$1,249,958Mark Lim · Ambergen, Inc · R44 · FY2020 · AG
AD04 disease-modifying drug for Alzheimer's - preclinical and IND-enabling studies
$1,249,957Carmela R Abraham · Advantage Therapeutics, Inc · R44 · FY2025 · AG
Comparative Effectiveness of Dementia Care Strategies in Underserved Communities
$1,249,939Barbara G Vickrey · Rand Corporation · RC4 · FY2010 · AG
Novel platform for research brain banking and characterization using integrated traditional and quantitative analyses to promote precision neuropathology of Alzheimer's disease
$1,249,822Christopher D Keene · Allen Institute · U19 · FY2020 · AG
Einstein Aging Study
$1,249,743Richard B. Lipton · Albert Einstein College Of Medicine, Inc · P01 · FY2015 · AG
Project 1 - Cognitive Function and Dementia
$1,249,672Lisa F Berkman · Harvard University D/B/A Harvard School Of Public Health · P01 · FY2024 · AG
Digital Accessible Remote Olfactory Mediated Health Assessments forPreclinical AD
$1,249,670Sean Reineke · Aromha, Inc. · R42 · FY2025 · AG
Development of Nav1.1 Enhancers to Treat Alzheimer's Disease
$1,249,502Michael Pleiss · Cure Network Dolby Acceleration Partners Llc · R44 · FY2023 · AG
Development of Nav1.1 Enhancers to Treat Alzheimer's Disease
$1,249,502Michael Pleiss · Cure Network Dolby Acceleration Partners Llc · R44 · FY2022 · AG
Small molecule targeting an epigenetic regulator for the treatment of osteoarthritis
$1,249,462Maddalena Adorno · Dorian Therapeutics, Inc. · U44 · FY2023 · AG
GLUCOSE METABOLISM AND THE DEFAULT MODE NETWORK IN HEALTH AND DISEASE
$1,249,427Marcus E Raichle · Washington University · P01 · FY2013 · NS
Clinical Development Enablement â Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimerâs Disease Drug Candidate T3D-959
$1,249,334John Didsbury · T3d Therapeutics, Inc. · R44 · FY2023 · AG
Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)
$1,249,244Charles Chiedu Nwaokobia · Evon Medics, Llc · R44 · FY2024 · AG
Development and Evaluation of Portable Compendium of Psychophysical and Physiological Tests for Alzheimer's Disease and Related Dementias (ADRD)
$1,249,244Charles Chiedu Nwaokobia · Evon Medics, Llc · R44 · FY2025 · AG
Active-H2O: Sensor driven smart faucet to empower independent living for individuals impacted by Alzheimers disease and dementia
$1,249,235John Steven Waddell · Nasoni Llc · R44 · FY2024 · AG
White matter damage in age-related cognitive decline
$1,249,219Thomas J Montine · University Of Washington · R01 · FY2010 · AG
Impact of sex differences in immune function on shared risk for cardiometabolic disorder & Alzheimer's disease
$1,249,153Jill M Goldstein · Massachusetts General Hospital · R01 · FY2024 · AG
Development of novel epigenetic biomarkers and detection reagents for aging
$1,249,147Sabrina Robin Hunt · Epicypher, Inc. · R44 · FY2025 · AG
Structurally Diverse GABA-A a5 Positive Allosteric Modulators for Treatment of MCI due to AD
$1,249,115Sharon Rosenzweig-Lipson · Agenebio, Inc. · R44 · FY2020 · AG
A high throughput multiplexed pipeline for models of Alzheimerâs Disease
$1,249,017Timothy M. Ragan · Tissuevision, Inc. · R44 · FY2023 · AG
Integrative Network Modeling of Cognitive Resilience to Alzheimer's Disease
$1,248,971Bin Zhang · Icahn School Of Medicine At Mount Sinai · R01 · FY2019 · AG
Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk
$1,248,699Victor Shifrin · Immunochem Therapeutics, Llc · R44 · FY2024 · AG
Bioinformatics and Data Integration Core
$1,248,658Gregory W Carter · University Of Pittsburgh At Pittsburgh · U19 · FY2024 · AG
A light exposure tracker designed to improve the circadian entrainment for Alzheimer Disease patients
$1,248,510Erik Page · Blue Iris Labs, Inc. · R44 · FY2022 · AG